Show simple item record

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Export
FieldValueLanguage
dc.contributor.authorCentonze, Diegoen
dc.contributor.authorRocca, Maria A.en
dc.contributor.authorGasperini, Claudioen
dc.contributor.authorKappos, Ludwigen
dc.contributor.authorHartung, Hans-Peteren
dc.contributor.authorMagyari, Melindaen
dc.contributor.authorOreja-Guevara, Celiaen
dc.contributor.authorTrojano, Mariaen
dc.contributor.authorWiendl, Heinzen
dc.contributor.authorFilippi, Massimoen
dc.date.accessioned2021-06-02T04:54:49Z
dc.date.available2021-06-02T04:54:49Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/2123/25166
dc.description.abstractCoronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal (https://coronavirus.jhu.edu/map.html). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.en
dc.language.isoenen
dc.rightsCopyright All Rights Reserveden
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleDisease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensusen
dc.typeArticleen
dc.identifier.doi10.1007/s00415-021-10545-2
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

Version history

There are no previous versions of the item available.